Physician profile
Scott Adelman
NPI 1750351847
$142,890.17
in general payments reported to CMS, 2019-2025
30 companies · $77K in 2025
The $77K reported for 2025 was more than what 99% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $28K · 2021: $3,481 · 2022: $5,185 · 2023: $9,117 · 2024: $20K · 2025: $77K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $98K · Travel and Lodging: $6,768 · Food and Beverage: $986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $97,736.67 |
| Travel and Lodging | $6,767.74 |
| Food and Beverage | $985.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elliquence, LLC | $96,095.77 | 2024-2025 | |
| Richard Wolf Medical Instruments Corp. | $30,318.77 | 2019-2021 | |
| Life Spine, INC. | $12,458.17 | 2022-2023 | Prolift Micro |
| Relievant Medsystems, INC. | $1,139.86 | 2019-2021 | |
| Riwospine, INC. | $1,085.77 | 2022-2023 | Spine |
| Ctl Medical Corporation | $371.16 | 2019-2022 | |
| Intrinsic Therapeutics | $253.46 | 2021 | |
| Integrity Implants INC. | $156.41 | 2022 | |
| Abbvie INC. | $147.16 | 2022-2023 | Ubrelvy, Qulipta |
| Spineology INC. | $127.06 | 2024-2025 | Optimesh Expandable Interbody Fusion System |
| Boston Scientific Corporation | $119.75 | 2019-2023 | |
| Circinus Medical Technology LLC | $77.23 | 2025 | Bolt Navigation |
| Allergan, INC. | $67.37 | 2020-2022 | |
| Pfizer INC. | $54.24 | 2019-2021 | |
| Expanding Innovations, INC. | $49.00 | 2024 | X-Pac |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $40.78 | 2019 | |
| Lilly USA, LLC | $35.76 | 2021 | |
| Amgen INC. | $34.22 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $33.87 | 2019 | |
| Nevro Corp. | $28.90 | 2022 | |
| Arbor Pharmaceuticals, INC. | $28.13 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $27.24 | 2021-2022 | |
| Spinal Elements, INC. | $24.13 | 2022 | |
| Active Medical, LLC | $23.95 | 2025 | |
| Avanos Medical | $19.32 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.38 | 2021 | |
| Medtronic USA, INC. | $14.52 | 2020 | |
| Biodelivery Sciences International, INC. | $13.37 | 2020 | |
| Lundbeck LLC | $13.25 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Adelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.